IRD vs. PBYI, BMEA, RENB, VTYX, MCRB, IFRX, SGMT, MNPR, CRBP, and NBTX
Should you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Puma Biotechnology (PBYI), Biomea Fusion (BMEA), Renovaro (RENB), Ventyx Biosciences (VTYX), Seres Therapeutics (MCRB), InflaRx (IFRX), Sagimet Biosciences (SGMT), Monopar Therapeutics (MNPR), Corbus Pharmaceuticals (CRBP), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.
Opus Genetics vs.
Puma Biotechnology (NASDAQ:PBYI) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
Puma Biotechnology currently has a consensus target price of $7.00, indicating a potential upside of 134.90%. Opus Genetics has a consensus target price of $8.00, indicating a potential upside of 595.65%. Given Opus Genetics' higher probable upside, analysts clearly believe Opus Genetics is more favorable than Puma Biotechnology.
Puma Biotechnology has a net margin of 9.56% compared to Opus Genetics' net margin of -324.45%. Puma Biotechnology's return on equity of 41.60% beat Opus Genetics' return on equity.
Puma Biotechnology received 549 more outperform votes than Opus Genetics when rated by MarketBeat users. However, 100.00% of users gave Opus Genetics an outperform vote while only 67.11% of users gave Puma Biotechnology an outperform vote.
In the previous week, Puma Biotechnology had 1 more articles in the media than Opus Genetics. MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.00 beat Puma Biotechnology's score of -0.50 indicating that Opus Genetics is being referred to more favorably in the news media.
Puma Biotechnology has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 23.7% of Puma Biotechnology shares are held by insiders. Comparatively, 6.6% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Puma Biotechnology has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.
Summary
Puma Biotechnology beats Opus Genetics on 12 of the 16 factors compared between the two stocks.
Get Opus Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Opus Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:IRD) was last updated on 1/22/2025 by MarketBeat.com Staff
